{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166182843",
    "name" : "Annotation of DPWG Guideline for atorvastatin and SLCO1B1",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : false,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1450415243,
        "date" : "2019-05-27T00:00:00-07:00",
        "description" : "Annotation current with November 2018 DPWG Guideline release",
        "type" : "Create",
        "version" : 0
      },
      {
        "id" : 1450820770,
        "date" : "2019-10-06T21:39:33.327-07:00",
        "description" : "No changes based on August 2019 guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450962620,
        "date" : "2020-02-10T09:46:49.659-08:00",
        "description" : "Fixed links to 2018 guideline pdfs.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451257940,
        "date" : "2020-08-31T17:59:15.027-07:00",
        "description" : "updated wording to reflect August 2020 update",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451471600,
        "date" : "2021-07-16T13:53:38.363-07:00",
        "description" : "fixed typo for 521 T>C in the table",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451492885,
        "date" : "2021-09-08T00:00:00-07:00",
        "description" : "Added extended dosing guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451704170,
        "date" : "2022-03-03T16:33:21.337-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451706180,
        "date" : "2022-03-07T14:33:51.811-08:00",
        "description" : "Added information about preemptive genotyping",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451732810,
        "date" : "2022-03-28T09:57:35.073-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451733288,
        "date" : "2022-03-28T14:32:45.557-07:00",
        "description" : "Updated link to testing guidance page",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451741444,
        "date" : "2022-04-05T11:10:05.219-07:00",
        "description" : "Added testing guidance tag",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451884091,
        "date" : "2022-09-16T09:42:55.737-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146486,
        "date" : "2023-07-03T13:39:57.943-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452411542,
        "date" : "2024-03-18T10:55:23.938-07:00",
        "description" : "Updated links for risk analysis pdf and preemptive testing page.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452423053,
        "date" : "2024-03-28T00:00:00-07:00",
        "description" : "Tags updated: [Alt Drug added]",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","crossReferences":[{"id":1450815695,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15113882,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2020","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2020.pdf","crossReferences":[{"id":1451257580,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2020.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2020.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","crossReferences":[{"id":1450415575,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : true,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Variant",
        "id" : "PA166154579",
        "symbol" : "rs4149056",
        "name" : "rs4149056",
        "version" : 6
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA448500",
        "name" : "atorvastatin",
        "version" : 22
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA134865839",
        "symbol" : "SLCO1B1",
        "name" : "solute carrier organic anion transporter family member 1B1",
        "version" : 49
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1450415241,
      "html" : "<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1450415242,
      "html" : "<p>Read more about how PharmGKB <a href=\"/page/dpwgMapping\">curates DPWG guidelines</a> using extra information provided by DPWG to enable the interactive genotype tool above.</p>\n<h3 id=\"august-2020-guideline-update\">August 2020 Guideline update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atorvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, they advise contacting their doctor in the event of muscle symptoms.</p>\n<p><em>Wording in table taken from <a download=\"DPWG_August_2020.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf\">Dutch guidelines August 2020 update</a></em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td><em>SLCO1B1</em> 521 CC</td>\n<td>atorvastatin</td>\n<td>The risk of myopathy may be increased. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase the atorvastatin plasma concentration.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative.<br/>Do not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n<tr>\n<td><em>SLCO1B1</em> 521 TC</td>\n<td>atorvastatin</td>\n<td>The risk of myopathy can be elevated. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase atorvastatin plasma concentrations.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative.<br/>Rosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_SLCO1B1_atorvastatin_4057-4058.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_SLCO1B1_atorvastatin_4057-4058.pdf\">Read for more information about this recommendation</a>, <a download=\"SLCO1B1.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/SLCO1B1.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_SLCO1B1_atorvastatin_4057-4058.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_SLCO1B1_atorvastatin_4057-4058.pdf\">DPWG risk analysis document</a> for atorvastatin and SLCO1B1:</p>\n<blockquote class=\"blockquote\">\n<p>The KNMP Pharmacogenetics Working Group considers genotyping before starting atorvastatin to be potentially beneficial for the prevention of side effects. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the KNMP Pharmacogenetics Working Group recommends adhering to the genedrug guideline.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<h3 id=\"november-2018-guideline\">November 2018 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atorvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, they advise contacting their doctor in the event of muscle symptoms.</p>\n<p><em>Wording in table taken from <a download=\"DPWG_November_2018.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a></em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>521 CC</td>\n<td>atorvastatin</td>\n<td>The genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n<tr>\n<td>521 TC</td>\n<td>atorvastatin</td>\n<td>The genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n</tbody>\n</table>\n",
      "version" : 8
    },
    "version" : 13
  }
}